WinstonWınston
Global Pharmatech logo

Global Pharmatech

GBLP
32
Medical - Pharmaceuticals · Healthcare
Price
$0.08
+0.00 (+0.00%)
Market Cap
$33.3M
Winston Score
32
Winston is serious
Below-average fundamentals — multiple weak pillars.

Share count rising — dilution

+1643.0% over 17y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 23.2M (2007) → 405.2M (2024)

Global Pharmatech, Inc. is a small specialty and generic drug manufacturer in the healthcare sector. The company develops and produces pharmaceutical products, likely including generic versions of established medications sold to hospitals, pharmacies, and healthcare distributors. It operates in a crowded industry where many companies compete to supply affordable medicines to patients and healthcare systems.

The company earns revenue primarily through the sale of its drug products, with a gross margin of around 25%, which is modest for the pharmaceutical industry. Its 26% return on invested capital suggests it deploys its resources reasonably efficiently relative to its small size. Generic drug manufacturers face ongoing pricing pressure as competitors enter the market with similar products, which can squeeze profits over time. The main risk for a company this size is its limited scale, which makes it harder to absorb regulatory costs, fund new drug development, or compete against larger manufacturers with broader product lines.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-71.4% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+100.0% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$0/ year

0.0% of revenue

Below sector average (18%)

Research and development spending

Insider Activity

83.7%ownership

Flat

Insiders holding steady — not selling despite ability to

Cash Position

Cash flow positive

$56,944 cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Company generates more cash than it spends — no dilution risk from fundraising

Revenue declining

Global Pharmatech's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
60.9%
Premium pricing power — 60.9% gross margin
Operating Margin
7.5%
Modest — 7.5% operating margin
ROCE
8.5%
Below par — 8.5% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
+14.2%
Fast-growing sales (14.2% YoY)
EPS YoY
N/A
Data not available
EPS Consistency
0/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
N/A
Data not available
FCF Margin
-57.5%
Burning cash (-57.5%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
N/A
Data not available
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
N/A
Data not available
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial